Repligen Corporation

Valuation Analysis

About the Company

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OP

Repligen Corporation Stock at a Glance

Repligen Corporation (RGEN) is currently trading at $130.59 with a market capitalization of $7.4B. The trailing P/E ratio stands at 143.51x, with a forward P/E of 51.3x. The 52-week range spans from $100.99 to $175.77; the current price is 25.7% below the yearly high. Year-over-year revenue growth stands at +14.8%. The net profit margin stands at 6.73%.

💰 Dividend

Repligen Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

19 analysts rate Repligen Corporation (RGEN) on consensus: Buy. The average price target is $176.11, implying +34.85% from the current price. Analyst price targets range from $142.00 to $220.00.

Repligen Corporation: The Investment Case in Detail

Repligen Corporation (RGEN) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 14.8% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 47.9% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Wall Street consensus sits at Buy with an average price target implying roughly 34.85% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Short interest sits at 10.6% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The EV/EBITDA multiple of 54.15x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The forward P/E of 51.3x is meaningfully below the trailing 143.51x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 34.85% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to market-like volatility, elevated short interest (10.6%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Repligen Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.